Chasing Bristol Myers and Biogen/Denali, CNS biotech raises $100M in dash toward clinic

In the months after South San Francisco-based Neuron23 announced a combined Series A and Series B, the biotech sat back down at the negotiating table for more funding. Suffice to say, the CNS biotech succeeded — and is now set with $100 million in cash that it secured late last year.